An interventional study of Reducing Attentional Interventions Therapy Treatment and Continue with the previous treatment plan in Tic Disorder and Provisional Tic Disorder, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment
Clarify the effectiveness and safety of "Reduced-Attention Intervention Therapy" in treating children with Provisional tic disorder （PTD） who mainly exhibit abnormal blinking behavior
Children diagnosed clinically with PTD primarily characterized by abnormal blinking were recruited from multiple clinical centers and randomly assigned to two groups. The behavioral intervention group received "attention-reduction intervention therapy," while the control group continued with their previous clinical treatment regimen. After the initial observation period, participants in both groups crossed over to receive the same attention-reduction intervention therapy for an additional treatment cycle. The study evaluated changes in Yale Global Tic Severity Scale Total Tic Severity Score (YGTSS-TTSS) scores at the end of each intervention cycle compared to baseline. This study is designed as a prospective, multicenter, randomized, controlled clinical trial to validate these findings.
102 studies on the registry are indexed under Tic Disorders; 26 are open to participants now.
This study's planned enrollment of 134 is above the median of 50 across 83 interventional studies indexed under Tic Disorders.
Browse Tic Disorders studies →Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 164 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The behavioral intervention group received the attention reduction intervention therapy.
Behavioral: Reducing Attentional Interventions Therapy Treatment
The control group did not receive the intervention therapy aimed at reducing attention, and subsequently was transferred to the attention reduction intervention therapy.
Other: Continue with the previous treatment plan
Reducing Attentional Interventions Therapy Treatment
Continue with the previous treatment plan
Score of the Yale Comprehensive Tics Severity Scale
Three evaluation researchers who had undergone unified training and were unaware of the group assignments independently conducted blinded scoring based on the standardized protocol and the medical records provided by the same guardian of the patients. The average value was then calculated.
Time frame: through study completion, an average of 6 months
YGTSS impairment subscale
Total score range: 0 - 50 points，A training evaluator and the guardian jointly completed
Time frame: through study completion, an average of 6 months
ocular and systemic Adverse Events (AEs)
ocular and systemic AEs will be summarized descriptively, including the number and proportion of participants with any adverse event or specific adverse-event subcategory, such as ocular versus non-ocular events, adverse events of special interest, and events leading to study discontinuation. If the severity grade changes, the event will be summarized according to the highest grade. Systemic and ocular adverse events will be summarized separately.
Time frame: through study completion, an average of 6 months
Self-Rating Depression Scale(SDS)
Number of items: 20,Data source: Filled out by the primary guardian
Time frame: through study completion, an average of 6 months
Gilles de la Tourette Syndrome-Quality of Life scale(GTS-QOL)
Number of items: 24, Data source: Filled out by the child and/or the primary caregiver
Time frame: through study completion, an average of 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2029, 38 months later.
Of 39 non-industry interventional studies with no phase under Tic Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 64. This study's planned 38 months is above that.
Counting every sponsor, half of 39 studies reached it within 28 months; a quarter within 16 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongshan Ophthalmic Center, Sun Yat-sen University →